Chuen-Pei Ng, Ph.D. - Publications

Affiliations: 
2001 University of California, Los Angeles, Los Angeles, CA 
Area:
Cell Biology, Oncology, Immunology

11/18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2005 Jia RR, Gou YL, Ho LS, Ng CP, Tan NH, Chan HC. Anti-apoptotic activity of Bak Foong Pills and its ingredients on 6-hydroxydopamine-induced neurotoxicity in PC12 cells. Cell Biology International. 29: 835-42. PMID 16154779 DOI: 10.1016/j.cellbi.2005.03.025  0.396
2002 Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Molecular Cancer Therapeutics. 1: 1051-8. PMID 12481428  0.717
2002 Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. The Prostate. 53: 286-99. PMID 12430140 DOI: 10.1002/Pros.10155  0.735
2002 Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Advances in Cancer Research. 85: 145-74. PMID 12374285 DOI: 10.1016/S0065-230X(02)85005-9  0.713
2002 Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 836-45. PMID 11895917  0.497
2001 Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 459-71. PMID 11759069 DOI: 10.1097/00002371-200111000-00003  0.701
2001 Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83. PMID 11751478  0.761
1999 Van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer and Prostatic Diseases. 2: 227-233. PMID 12497168 DOI: 10.1038/Sj.Pcan.4500373  0.657
1999 Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802. PMID 10493964 DOI: 10.3892/Ijo.15.4.793  0.71
1997 Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 963-72. PMID 9815772  0.663
1997 Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cellular Immunology. 180: 70-83. PMID 9316641 DOI: 10.1006/Cimm.1997.1169  0.644
Low-probability matches (unlikely to be authored by this person)
2003 Chow JP, Siu WY, Fung TK, Chan WM, Lau A, Arooz T, Ng CP, Yamashita K, Poon RY. DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase. Molecular Biology of the Cell. 14: 3989-4002. PMID 14517313 DOI: 10.1091/Mbc.E03-03-0168  0.17
2009 Chen J, Ng CP, Tsang LL, Ho LS, Xu PH, Rowlands DK, Gao JY, Chung YW, Li TY, Chan HC. Altered expression of inflammatory cytokine receptors in response to LPS challenge through interaction between intestinal epithelial cells and lymphocytes of Peyer's patch. Cell Biology International. 33: 369-75. PMID 19385035 DOI: 10.1016/j.cellbi.2009.01.004  0.151
2009 Yin LL, Chung CM, Chen J, Fok KL, Ng CP, Jia RR, Ren X, Zhou J, Zhang T, Zhao XH, Lin M, Zhu H, Zhang XH, Tsang LL, Bi Y, et al. A suppressor of multiple extracellular matrix-degrading proteases and cancer metastasis. Journal of Cellular and Molecular Medicine. 13: 4034-41. PMID 19017363 DOI: 10.1111/J.1582-4934.2008.00576.X  0.121
2005 Ajonuma LC, Tsang LL, Zhang GH, Wong CH, Lau MC, Ho LS, Rowlands DK, Zhou CX, Ng CP, Chen J, Xu PH, Zhu JX, Chung YW, Chan HC. Estrogen-induced abnormally high cystic fibrosis transmembrane conductance regulator expression results in ovarian hyperstimulation syndrome. Molecular Endocrinology (Baltimore, Md.). 19: 3038-44. PMID 16051669 DOI: 10.1210/me.2005-0114  0.1
2006 Chen J, Ng CP, Rowlands DK, Xu PH, Gao JY, Chung YW, Chan HC. Interaction between enteric epithelial cells and Peyer's patch lymphocytes in response to Shigella lipopolysaccharide: effect on nitric oxide and IL-6 release. World Journal of Gastroenterology : Wjg. 12: 3895-900. PMID 16804978  0.098
2004 Ng CP, Lee HC, Ho CW, Arooz T, Siu WY, Lau A, Poon RY. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. The Journal of Biological Chemistry. 279: 8808-19. PMID 14681223 DOI: 10.1074/Jbc.M312215200  0.056
2004 Chen J, Tsang LL, Ho LS, Rowlands DK, Gao JY, Ng CP, Chung YW, Chan HC. Modulation of human enteric epithelial barrier and ion transport function by Peyer's patch lymphocytes. World Journal of Gastroenterology. 10: 1594-9. PMID 15162532  0.046
Hide low-probability matches.